Two methods are described for the simultaneous determination of Atorvastatin calcium and Ezetimibe in binary mixture. The first method was based on UV-spectrophotometric determination of two drugs, using simultaneous equation method. It involves absorbance measurement at 232.5 nm (λ max of Ezetimibe) and 246.0 nm (λ max of Atorvastatin calcium) in methanol; linearity was obtained in the range of 5 -25 µg.mL -1 for both the drugs. The second method was based on HPLC separation of the two drugs in reverse phase mode using Luna C 18 column. Linearity was obtained in the concentration range of 8-22 µg.mL -1 for both the drugs. Both these methods have been successively applied to pharmaceutical formulation and were validated according to ICH guidelines.
Introduction:
Atorvastatin calcium chemically [R-(R, R*)]-2-(4-flurophenyl)-β,δ-dihydroxy-5(1-methylethyl)-3-phenyl-4-[phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1) trihydrate, is a synthetic HMG -CoA reductase inhibitor [1] . It has been demonstrated to be efficacious in reducing both cholesterol and triglycerides [2] . The chemical structure of Atorvastatin calcium is shown in Fig 1. The typical dose of Atorvastatin calcium is 10-80 mg per day and it reduces 40-60% LDL [3] . Literature survey reveled that various analytical methods such as HPLC [4, 5] , GC-MS [6] , LC-MS [7] , HPLC-Electrospray tendem mass spectrometry [8] and HPTLC [9] 
Ezetimibe chemically 1-(-4-flurophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-
azeti-dinone, is a selective cholesterol absorption inhibitor [10] , which potentially inhibits the absorption of biliary and dietary cholesterol [11] . Additional studies in human indicated that ezetimibe does not affect serum fat -soluble vitamins [12] . The dose of Ezetimibe is 10 mg daily, when added on to statin therapy there is an increase in the lipid lowering effect [13] . The structure of Ezetimibe is shown in Fig 2. There are very few methods reported for estimation of Ezetimibe in pharmaceutical dosage form, which includes a validated RP -HPLC [14] , spectrophotometric method using floin -Ciocalteu reagent [15] . India, used without further purification and certified to contain 99.53 % (w/w) and 99.66% (w/w), respectively on dried basis. All chemicals are of HPLC grade and were purchased from Qualigens fine Chemicals, Mumbai, India.
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UV-spectrophotometry:
UV-Vis spectrophotometer 1601 (Shimadzu, Japan) with spectral bandwidth of 2 nm and 10 mm matched quartz cells was used.
Standard stock solutions of 100 µg.mL -1 were prepared by dissolving 10 mg of each in 100 mL of methanol. From these stock solutions, working standard solutions having concentration 15 µg.mL -1 each were prepared by appropriate dilutions. They were scanned in the wavelength range of 400−200 nm and the overlain spectrum was obtained (Fig 3) . Two wavelengths 232.5 nm (λ max of Ezetimibe) and 246.0 nm (λ max of Atorvastatin calcium) were selected for the formation of simultaneous equation. The calibration curves were found to be linear in the concentration range of 5− 25 µg.mL -1 , for each drug. The absorptivity coefficients of each drug at both wavelengths were determined. The concentration of two drugs in the mixture were calculated using equations [16] , (Table 1) . Different mobile phases were tested in order to find the best conditions, for separating both the drugs simultaneously. The optimal composition of mobile phase was determined to be Ammonium acetate buffer pH 5.0: Acetonitrile: Triethylamine (50:50:0.2, v/v). The flow rate was set to 1 mL.min -1 and UV detection was carried out at 240 nm. Ibuprofen was used as an internal standard.
Stock solution was prepared by dissolving 10 mg of Atorvastatin calcium and Ezetimibe in 100 mL volumetric flask with methanol. 10 mg of Ibuprofen (internal standard) was taken in separate 100 mL volumetric flask and dissolved in methanol. 
Analysis of Pharmaceutical Dosage Forms
To determine the content of Atorvastatin calcium and Ezetimibe simultaneously in tablets (label claim: 10 mg Atorvastatin calcium and 10 mg Ezetimibe, film coated); twenty tablets were weighed; their average weight determined and were finely powdered. The correct amount of powder was dissolved in methanol by stirring for 30 min. The excipients were separated by filtration. After filtration, an appropriate amount of internal standard was added and diluted up to mark with methanol. Appropriate aliquots were subjected to above methods and the amount of Atorvastatin calcium and Ezetimibe were determined. The results are reported in Table 2 . 
Recovery studies
To check the accuracy of the developed methods and to study the interference of formulation additives, analytical recovery experiments were carried out by standard addition method, at 80, 100
and 120 % level. From the total amount of drug found, the percentage recovery was calculated. The results are reported in Table 3 .
Results and Discussion
Both, UV spectrophotometric and HPLC methods were found to be simple, accurate, economic and rapid for routine simultaneous estimation of Atorvastatin calcium and Ezetimibe, in tablet dosage forms. For UV spectrophotometric method, linearity was obtained in concentration range of 5 -25 µg .mL -1 , for both the drugs; with regression 0.9998 and 0.9999, intercept -0.0677 and -0.0043 and slope 0.0457 and 0.0391 for Atorvastatin calcium and Ezetimibe, respectively.
Recovery was in the range of 99 -101 %; the value of standard deviation and % R.S.D. were found to be < 2 %; shows the high precision of the method. In HPLC method, HPLC conditions were optimized to obtain, an adequate separation of Sample -to sample precision and accuracy were evaluated using, three samples of three different concentrations, which were prepared and analyzed on same day. Day -to day variability was assessed using three concentrations analyzed on three different days, over a period of one week.
These results show the accuracy and reproducibility of the assay. Thus, it was concluded that there was no significant difference on the assay, which was tested on an intra -day and inter -day basis.
The % R.S.D. values reported in Table 5 , shows that proposed methods provides acceptable intraday and inter -day variation of Atorvastatin calcium and Ezetimibe.
Ruggedness of the proposed methods was determined by analysis of aliquots from homogeneous slot in different laboratories, by different analysts, using similar operational and environmental conditions; the % R.S.D. reported in Table 5 was found to be less than 2 %.
The proposed methods are accurate, simple, rapid and selective for the simultaneous estimation of Atorvastatin calcium and Ezetimibe in tablet dosage form by internal standardization method.
Hence, it can be conveniently adopted for the routine quality control analysis in the combination 
